Table 2. Description of the population included by type of intervention and treatment group.
Study Study Design Inclusion criteria Treatment group Treatment group P
N
Cycles		 Age
(years)		 Ovarian reserve* Nº ET (n) N
Cycles		 Age
(years)		 Ovarian
reserve*		 Nº ET (n)
Ultralong GnRH protocol Long GnRH protocol
GnRH protocol before COS and fresh ET Hou et al 2020 Retrospective cohort Infertile patients whith adenomyosis. Age<38, FSH<10, AFC>10, first IVF attemps, no PCOS, no imune diseases, no myomas, no previous myomectomy, no uterine malformations, no ednometriosis 362 31.9
(30-35)		 6.5
(5.34-7.58)		 NR 127 31.8
(29-34)		 6.3
(5.4-7.1)		 NR NS
Chen et al., 2020 Retrospective cohort Infertile patients with adenomyosis 52 33.5
(31-36.75)		 6.19
(4.99-7.39)		 2
(2-3)		 162 33.5
(30-36.75)		 5.74
(4.88-6.74)		 2
(2-3)		 NS
Lan et al., 2021 Retrospective cohort Infertile patients whith adenomyosis. Age<42, no myomas, no previous uterine surgery, no uterine malformations, no untreated hydrosalpinx 237 33.55±4.12 2.37
(1.35-4.17)		 2.05±0.57 134 33.99±4.08 1.93
(1.13-4.18)		 2.05±0.55 NS
Wu et al., 2022 Retrospective cohort Infertile patients whith adenomyosis. Age<42, no submucosal myoma or myoma<2cm, no previous uterine surgery, no uterine malfromatios, no untreated hydrosalpix, <3 attemps on ET 259 33.35±4.16 8.09±3.74 2.01±0.54a 115 33.88±4.13 8.80±4.11 1.95±0.5a 0.11a
Ge et al., 2023 Retrospective cohort Infertile patients whith adenomyosis. Age<42, no intrauterine lesions, no uterine malformations, no untreated hydrosalpinx 108 34
(31-37)		 1.65
(1.06-3.03)b		 NR 56 32.5
(30-36)		 2.75
(1.66-3.90)b		 NR 0.11b
Ultralong GnRH protocol Antagonist GnRH protocol
Park et al., 2016 Retrospective cohort Infertile patients whith adenomyosis, excluding other causes of infertility other than adenomyosis 150 35.2±3.5 8.2±7.0 2.9±1.1 147 36.1±3.3 10.5±2.3 2.7±1.1 NS
Ge et al., 2023 Retrospective cohort (see above) 162 34 (31-37) 1.65
(1.06-3.03)		 NR 34 33.5 (32-41) 1.32
(0.92-3.37)		 NR NS
Long GnRH protocol Antagonist GnRH protocol
Ge et al., 2023 Retrospective cohort (see above) 56 32.5
(32-1)		 2.75
(1.66-390)		 NR 34 33.5
(32-41)		 1.32
(0.92-3.37)		 NR NS
Short GnRH protocol Antagonist GnRH protocol
Ge et al., 2023 Retrospective cohort (see above) 59 33.5
(32-41)		 1.30
(0.77-1.90)		 NR 34 33.5
(32-41)		 1.32
(0.92-3.37)		 NR NS
Pretreatment before FET GnRH pretreatment No pretreatment
Niu et al., 2013 Retrospective cohort Infertile patients with adenomyosis, Age <38, ≤ 1 previous FET, normal uterine cavity, no previous myomectomy, no untreated hydrosalpinx, no stage IV endometriosis 194 32.11±4.02 7.46±2.27 1.96±.04 145 31.52±4.03 7.19±1.33 1.94±0.37 NS
Zhang et al., 2022 Retrospective cohort Infertile patients with adenomyosis. Age ≤45, uterine volume between 56-100cm3, no endocrine or autoimmune disorders, normal kariotype in both partners, normal uterine cavity (no intrauterine adhesions, no submucosal myomas or myomas <50mm) 45 33.5±3.7 3.36± 1.48±0.6 218 34.8±4.7 3.50±2.9 1.49±0.6 NS
Li et al., 2021 Retrospective cohort Infertile patients with adenomyosis. Age <45, no uterine malformations, no endometriosis, no untreated hydrosalpinx, no PCOS, normal kariotype in both partners 160 35.56±4.49 6.54±1.89 1.11±0.19 181 35.25±4.95 6.32±2.04 1.12±0.21 NS

* Ovarian reserve: AMH expressed in ng/ml or basal FSH in italics and expressed in mlU/ml when AMH was not available; PCOS = Polycystic Ovarian Syndrome.